Immunotherapy of prostate cancer

被引：3

作者：

Freedland S.J. ^{[1
]}

Pantuck A.J. ^{[1
]}

Weider J. ^{[1
]}

Zisman A. ^{[1
]}

Belldegrun A.S. ^{[1
]}

机构：

[1] Los Angeles School of Medicine, Department of Urology, University of California, 10833 Le Conte Avenue, Room 66-118 CHS, Los Angeles, 90095-1738, CA

来源：

Current Urology Reports | 2001年 / 2卷 / 3期

关键词：

Dendritic Cell; Epidermal Growth Factor Receptor; Human Clinical Trial; Prostatic Acid Phosphatase; Tumor Vaccine;

D O I：

10.1007/s11934-001-0086-9

中图分类号：

学科分类号：

摘要：

The realization that prostate cancer is an immunogenic tumor, in conjunction with the discovery of novel methods for priming the immune system to generate an antitumor response, has resulted in several new approaches for prostate cancer immunotherapy. Based on these various approaches, several human clinical trials have begun using immune-based therapies for prostate cancer. These approaches can be divided into cytokine-based therapies, tumor-associated antigen-based therapies, tumor vaccines, and dendritic cell-based therapies. This review summarizes the latest findings from each of these approaches and gives results from the few completed human clinical trials. © 2001, Current Science Inc.

引用

页码：242 / 247

页数：5

共 57 条

[1]

Sokoloff M.H., Tso C.L., Kaboo R., Et al., In vitro modulation of tumor progression-associated properties of hormone refractory prostate carcinoma cell lines by cytokines, Cancer, 77, (1996)

[2]

Steiner M.S., Gingrich J.R., Gene therapy for prostate cancer: where are we now?, J Urol, 164, (2000)

[3]

Morgan D.A., Ruscetti F.W., Gallo R., Selective in vitro growth of T lymphocytes from normal human bone marrows, Science, 193, (1976)

[4]

Hautmann S.H., Huland E., Huland H., Local intratumor immunotherapy of prostate cancer with interleukin-2 reduces tumor growth, Anticancer Res, 19, (1999)

[5]

Kocheril S.V., Grignon D.J., Wang C.Y., Et al., Responsiveness of human prostate carcinoma bone tumors to interleukin-2 therapy in a mouse xenograft tumor model, Cancer Detect Prev, 23, (1999)

[6]

Maffezzini M., Simonato A., Fortis C., Salvage immunotherapy with subcutaneous recombinant interleukin 2 (rIL-2) and alpha-interferon (A-IFN) for stage D3 prostate carcinoma failing second-line hormonal treatment, Prostate, 28, (1996)

[7]

National Cancer Institute: Cancer Clinical Trials, (2001)

[8]

Kawakita M., Rao G.S., Ritchey J.K., Et al., Effect of canarypox virus (ALVAC)-mediated cytokine expression on murine pros-tate tumor growth, J Natl Cancer Inst, 89, (1997)

[9]

Trachtenberg J., Dancey J., Toi H., Et al., A phase I trial of adenovector mediated delivery of interleukin-2 (AdCAIL-2) in locally advanced prostate cancer, J Urol, 163, (2000)

[10]

Felgner P.L., Gadek T.R., Holm M., Et al., Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure, Proc Natl Acad Sci U S A, 84, (1987)

← 1 2 3 4 5 6 →